Application | Comment | Organism |
---|---|---|
medicine | a range of fibrinolytic kinetic values and the contribution of thrombin activatable fibrinolysis inhibitor in normal subjects are established. Study of disease states involving potential hypofibrinolysis can be conducted using this system to link fibrinolytic vulnerability and thrombophilia | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
potato carboxypeptidase inhibitor | fibrinolytic vulnerability and the contribution of thrombin activatable fibrinolysis inhibitor to fibrinolytic defenses in normal subjects are analysed: Plasma from 30 normal subjects is exposed to tissue factor/kaolin and tissue-type plasminogen activator. Prior to activation of coagulation, samples are either not exposed or exposed to potato carboxypeptidase inhibitor (25 microg/ml, a thrombin activatable fibrinolysis inhibitor). Thrombin activatable fibrinolysis inhibitor's inhibition decreases the time to onset of maximum fibrinolysis by 45%, increases the rate of maximum lysis by 50%, and decreases clot lysis time by 45% | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood plasma | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
TAFI | - |
Homo sapiens |
thrombin-activatable fibrinolysis inhibitor | - |
Homo sapiens |